WebMay 7, 2024 · The US Food and Drug Administration (FDA) has announced the approval of dapagliflozin (Farxiga) to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status. Having already received approval for a similar indication in type 2 ... WebApr 9, 2024 · In the placebo-controlled DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), dapagliflozin reduced the risk of total …
Dapagliflozin Receives FDA Approval for Heart Failure, …
WebOct 3, 2024 · Results of the trial suggested use of dapagliflozin was associated with an 18% (HR, 0.82 [95% CI, 0.73-0.92]; P <.001) relative risk reaction for the primary composite endpoint of cardiovascular death or worsening heart failure, with this effect consistent in those with an ejection fraction greater than 60% compared to the overall study ... WebMar 31, 2024 · In this analysis, investigators found dapagliflozin reduced the risk of worsening heart failure, cardiovascular death, and all-cause mortality, irrespective of … flannel white vest
NICE Recommends Dapagliflozin for Heart Failure
WebIts prognostic importance and relationship with kidney function in patients with heart failure with reduced ejection fraction receiving contemporary treatment are uncertain. We … WebNov 13, 2024 · Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to prevent primary and secondary … WebAug 27, 2024 · Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or … flannel what matches with blue chinos